全文获取类型
收费全文 | 2116篇 |
免费 | 141篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 24篇 |
儿科学 | 88篇 |
妇产科学 | 67篇 |
基础医学 | 230篇 |
口腔科学 | 21篇 |
临床医学 | 230篇 |
内科学 | 394篇 |
皮肤病学 | 97篇 |
神经病学 | 148篇 |
特种医学 | 86篇 |
外科学 | 274篇 |
综合类 | 24篇 |
一般理论 | 3篇 |
预防医学 | 175篇 |
眼科学 | 53篇 |
药学 | 135篇 |
中国医学 | 3篇 |
肿瘤学 | 212篇 |
出版年
2023年 | 22篇 |
2022年 | 16篇 |
2021年 | 54篇 |
2020年 | 43篇 |
2019年 | 66篇 |
2018年 | 74篇 |
2017年 | 42篇 |
2016年 | 67篇 |
2015年 | 65篇 |
2014年 | 65篇 |
2013年 | 120篇 |
2012年 | 126篇 |
2011年 | 145篇 |
2010年 | 92篇 |
2009年 | 93篇 |
2008年 | 130篇 |
2007年 | 141篇 |
2006年 | 127篇 |
2005年 | 104篇 |
2004年 | 96篇 |
2003年 | 106篇 |
2002年 | 99篇 |
2001年 | 40篇 |
2000年 | 28篇 |
1999年 | 30篇 |
1998年 | 19篇 |
1997年 | 17篇 |
1996年 | 14篇 |
1995年 | 6篇 |
1994年 | 6篇 |
1993年 | 11篇 |
1992年 | 16篇 |
1991年 | 15篇 |
1990年 | 10篇 |
1989年 | 14篇 |
1988年 | 14篇 |
1987年 | 17篇 |
1986年 | 9篇 |
1985年 | 5篇 |
1984年 | 6篇 |
1983年 | 8篇 |
1982年 | 6篇 |
1980年 | 4篇 |
1979年 | 8篇 |
1978年 | 5篇 |
1976年 | 5篇 |
1975年 | 7篇 |
1973年 | 6篇 |
1972年 | 9篇 |
1970年 | 7篇 |
排序方式: 共有2264条查询结果,搜索用时 31 毫秒
1.
OBJECTIVE: This study was conducted to compare an otolaryngologist's experience with a cohort of epilepsy patients implanted with a vagal nerve stimulator (VNS) to previously published data. METHODS: Demographics, preoperative seizure frequency, medications, and complications were retrospectively collected from patients implanted by the senior author. Postoperative medications and seizure frequency were obtained from referring neurologists. RESULTS: Seventeen patients were implanted over a 24-month period. Average age was 28.3 years. Patients presented with petit mal (n = 3), tonic-clonic (n = 6), complex partial (n = 5), and grand mal (n = 8) seizures. Mean follow-up postimplantation was 13.5 months. Most patients had at least a 50% reduction of seizure frequency, with 3 patients being seizure free. There were no postoperative infections. One patient had left vocal cord immobility. The most common side effect was voice disturbance during device activation. CONCLUSION: Otolaryngologists are well equipped to perform VNS implantation and to diagnose and treat possible laryngeal side effects. EBM rating: C-4. 相似文献
2.
Sherry X Yang Richard M Simon Antoinette R Tan Diana Nguyen Sandra M Swain 《Clinical cancer research》2005,11(17):6226-6232
PURPOSE: To delineate gene expression patterns and profile changes in metastatic tumor biopsies at baseline and 1 month after treatment with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib in patients with metastatic breast cancer. EXPERIMENTAL DESIGN: Patients were treated with 150 mg of oral erlotinib daily. Gene expression profiles were measured with Affymetrix U133A GeneChip and immunohistochemistry was used to validate microarray findings. RESULTS: Estrogen receptor (ER) status by immunohistochemistry is nearly coincided with the two major expression clusters determined by expression of genes using unsupervised hierarchical clustering analysis. One of 10 patients had an EGFR-positive tumor detected by both microarray and immunohistochemistry. In this tumor, tissue inhibitor of metalloproteinases-3 and collagen type 1 alpha 2, which are the EGF-down-regulated growth repressors, were significantly increased by erlotinib. Gene changes in EGFR-negative tumors are those of G-protein-linked and cell surface receptor-linked signaling. Gene ontology comparison analysis pretreatment and posttreatment in EGFR-negative tumors revealed biological process categories that have more genes differentially expressed than expected by chance. Among 495 gene ontology categories, the significant differed gene ontology groups include G-protein-coupled receptor protein signaling (34 genes, P = 0.002) and cell surface receptor-linked signal transduction (74 genes, P = 0.007). CONCLUSIONS: ER status reflects the major difference in gene expression pattern in metastatic breast cancer. Erlotinib had effects on genes of EGFR signaling pathway in the EGFR-positive tumor and on gene ontology biological process categories or genes that have function in signal transduction in EGFR-negative tumors. 相似文献
3.
Circulating immune complex levels in patients with schistosomiasis and complications 总被引:3,自引:0,他引:3
A M Ghanem F N Boctor S Bassily H Shaheen A Ahmed L Garges 《Transactions of the Royal Society of Tropical Medicine and Hygiene》1987,81(5):773-777
Circulating immune complexes (CIC), adult schistosome antibody, and total immunoglobulin concentrations were estimated in sera from 35 chronic Schistosoma mansoni patients with different infection intensities and different pathological complications. High CIC levels were present in about one-third (10/35) of the sera. Most of the patients (9/10) with elevated CIC levels also had hepatomegaly or hepatosplenomegaly. This finding is significant in the pathogenesis of schistosomal liver fibrosis and may also apply to other liver diseases, especially cirrhosis. No correlation was found between infection intensity as judged by stool egg counts and CIC levels. A reverse relationship was observed between the level of anti-adult worm IgG and CIC levels. CIC levels were elevated within 7 and 28 days after treatment in most patients. Hypergammaglobulinaemia was detected in most sera. 相似文献
4.
5.
Scarlett Lin Gomez Cynthia D O'Malley Antoinette Stroup Sarah J Shema William A Satariano 《BMC cancer》2007,7(1):193
Background
Colorectal cancer, if detected early, has greater than 90% 5-year survival. However, survival has been shown to vary across racial/ethnic groups in the United States, despite the availability of early detection methods. 相似文献6.
Margaretha Jennerwein Ronald Gust Richard Müller Helmut Schnenberger Jürgen Engel Martin R. Berger Dietrich Schmhl Siegfried Seeber Reinhanidt Osieka Ghanem Atassi Danile Marchal-De Bock 《Archiv der Pharmazie》1989,322(2):67-73
The activity of stereoisomeric [1,2-bis(3-hydroxyphenyl)ethylenediamine] dichloroplatinum(II)-complexes (1-PtCl2,R,S; 2-PtCl2, R,R/S,S; 3-PtCl2, R,R; 4-PtCl2, S,S) on several tumor models (MDA-MB 231 breast cancer cell line; P 388 leukemia, mouse; L 1210 leukemia, mouse; L 5222 leukemia, rat; Ehrlich ascites tumor, mouse--wildtype; cisplatin-, etoposide-, cyclophosphamide-, and daunomycin-resistant, resp.) is described. For comparison the analogous [1,2-bis(4-hydroxyphenyl)ethylendiamine]dichloroplatinum (II)-complexes (5-PtCl2, R, S; 6-PtCl2, R,R/S,S; 7-PtCl2, R,R; 8-PtCl2, S,S) and cisplatin are used. 1-PtCl2 to 4-PtCl2 (OH in 3,3'-positions) show their maximum antitumor effect at lower doses than 5-PtCl2 to 8-PtCl2 (OH in 4,4'-positions). 2-PtCl2 and 6-PtCl2 (R,R/S,S) are more active than 1-PtCl2 and 5-PtCl2 (R,S). 4-PtCl2 and 8-PtCl2 (S,S) are superior to 3-PtCl2 and 7-PtCl2 (R,R). On the L 5222 leukemia 2-PtCl2 (R,R/S,S), 4-PtCl2 (S,S) and 8-PtCl2 (S,S) markedly surpass cisplatin. Strong effects are produced by 2-PtCl2 to 4-PtCl2 on the Ehrlich ascites tumor (wildtype, cisplatin-, etoposide-, cyclophosphamide-, and daunomycin-resistant, resp.). The combination of 4-PtCl2 with cisplatin results in a weakly synergistic effect. 相似文献
7.
Joseph Cofrancesco Nina Shah Khalil G Ghanem Adrian S Dobs Robert S Klein Kenneth Mayer Paula Schuman David Vlahov Anne M Rompalo 《Gynecological endocrinology》2006,22(5):244-251
Drug use and HIV infection may affect sex hormone levels in women. One hundred and ninety-six women with and without a history of illicit drug use (50 HIV-negative and 148 HIV-infected), with regular menses, who never used antiretrovirals, were evaluated. Luteinizing hormone levels were significantly higher in women with a CD4 cell count <200/microl (p < 0.002). Current methadone use was associated with lower levels of total testosterone (p = 0.03) and higher levels of prolactin (p = 0.002); mean estradiol levels were 43% lower in women who used intravenous drugs (p < 0.001). Alcohol and crack cocaine use was not associated with sex hormone levels. Age, race, body mass index and degree of HIV immunosuppression were also associated with differences in sex hormone levels. 相似文献
8.
9.
Alex L. van Bemmel Rutger H. van den Hoofdakker Domien G. M. Beersma Antoinette L. Bouhuys 《Psychopharmacology》1993,113(2):225-230
Drug-induced improvement of depression may be mediated by changes in sleep physiology. The aim of this study was to relate changes in sleep polygraphic variables to clinical state during treatment with citalopram, a highly specific serotonin uptake inhibitor. Sixteen patients took part. The study was single-blind and uncontrolled. A 1-week wash-out period was followed by 1 week of placebo administration, a medication period of 5 weeks, and a 1-week placebo period. For the entire group a significant decrease of rapid eye movement sleep (REMS) and a significant lengthening of REMS latency were observed initially as well as at the end of treatment. No changes in sleep continuity were found, but non-REMS stage 2 (percentage) was significantly increased. On the basis of clinical change, as expressed by the scores of the Hamilton Rating Scale for Depression, at the end of the citalopram treatment the patient group was split in two halves: eight less and eight more improved patients. The groups did not differ with respect to any sleep polygraphic varible. 相似文献
10.